alexa Efficacy Of Combination Mucosal Vaccination And Immunotherapy Strategies For The Treatment Of HPV-associated Cancers
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

K Jagannadha Sastry
ScientificTracks Abstracts: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.020
High-risk human papillomaviruses (most frequently HPV-16) are sexually transmitted infections responsible for preand cancerous lesions of cervix as well as a high percentage of anal, vaginal, vulvar, penile and oropharyngeal cancers. Effective vaccines based on the HPV core protein L1 currently approved for prevention of new HPV infections in young adults are ineffective to treat existing infections/lesions which predominantly express the viral E6 and E7 oncogenes but not L1. Therapeutic vaccines based on the E6 and E7 tumor antigens are urgently needed, especially for people in the developing world to combat HPV diseases. We discovered specific HPV-16 E6 and E7 peptides for which memory T cell immunity is associated with recurrence-free survival in women treated for HPV pre-cancerous cervical lesions. In mouse model studies, mucosal intranasal immunization employing these E6 and E7 peptides admixed with novel adjuvants induced HPV-specific systemic and mucosal effector CD4/CD8 T cell responses that prevented HPV+ tumor formation. Therapeutic mucosal intranasal vaccination with these peptides in combination with adjuvants significantly reduced HPV tumor growth in mice affording long term survival advantage. Furthermore, combination of intranasal vaccination with the E6 and E7 peptides with immune check point blockade antibody treatmentresulted in significant tumor regression leading to eradication. These data support future clinicaltesting of combination vaccine immunotherapy strategies for effective treatment and possibly eradication of preand cancerous HPV lesions.
Jagan Sastry is a professor in the departments of Immunology and Veterinary Sciences at The University of Texas MD Anderson Cancer Center, Houston, TX. His research over the past 25+ years, supported by NIH, industrial and private funding in the broad areas of viral oncology and immunology, focuses on understanding the biology, pathology, immunology and genetics of HPV-associated cancers and HIV-induced AIDS. The overall goals are to develop vaccines and therapeutics for prediction, treatment and prevention. He actively mentors graduate/undergraduate students and post-doctoral fellows as well as serves on NIH study sections and editorial boards of scientific journals.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version